Navigation Links
Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
Date:1/12/2009

cation. Sangamo has established strategic partnerships with companies outside the human therapeutic area including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sigma-Aldrich's and Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFNs, potential therapeutic, medical research and pharmaceutical applications of the ZFN technology and the timing of initiation of clinical trials by Sangamo. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and Sigma-Aldrich to develop commercially viable products and technological developments by our competitors. See the SEC filings, and in particular, the risk factors described in the Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q of each of Sangamo and Sigma-Aldrich. Neither Sigma-Aldrich nor Sangamo assumes any obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 , Not for ... into or from any jurisdiction where to do so would ... Shire plc ("Shire" or the "Company") (LSE: SHP, ... afternoon.  Shire confirms it has held a meeting with representatives ... Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Helena Rojas to Director of Global Business Development Operations , ... ... Ltd., a leading provider of multilingual localization, testing and outsourced software ... to Vice President of Global Business Development and Helena Rojas to ...
... China, March 4 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... manufacturer and,marketer of medical devices worldwide, today announced ... Officer of the Company effective as of May ... step down from the role of Chief,Financial Officer ...
... 4 The Healthcare practice at Frost ... 2009 Quarterly Analyst Briefing Presentation on the North ... March 5, 2009 at 10:00 a.m. PST. (Logo: ... growth and is experiencing several notable trends, such ...
Cached Biology Technology:Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3Mindray Appoints Mr. Ronald Ede as Chief Financial Officer 2Mindray Appoints Mr. Ronald Ede as Chief Financial Officer 3Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2
(Date:7/11/2014)... When researchers at the National Institute of Standards ... do their work more effectively, they often prove ... Such was the case recently for M. Lorna ... in the growing specialization of glycomics. Glycomics is ... called glycans that are attached to proteins and ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... evidence that under the normal circumstances, astrocytes ... maintain neuronal environment, and exhibit therapeutic and ... disease. Previous studies have found that nerve ... chemical induction have reduced viability, which produces ... Xiaodong Yuan, Kailuan General Hospital, Hebei United ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... with colleagues from the Botswana National Museum shed new ... to southern Africa and from where. A domestic cow ... from a site at Toteng, located in the Kalahari ... Accelerator Mass Spectrometry (AMS) radiocarbon technique, provides the oldest ...
... found that the two primary areas of the human ... cortex used in higher-level thought undergoes more extensive changes ... such as heartbeat, breathing and balance. Their work, based ... of human and chimpanzee brains, also shows that the ...
... first time used gene therapy to successfully treat heart ... model that is genetically susceptible to a human muscular ... journal Circulation, the authors say that this is the ... the body. , "Previous attempts at systemic gene therapy ...
Cached Biology News:Human cerebellum and cortex age in very different ways 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 3Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 4
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... rolled steel with stove enamel coated (RAL 7035 ... Front, back and side windows ... lamps Internal adjustable tempered glass shelf ... Lighting 600 lux ...
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Biology Products: